Drapolene Cream
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Drapolene Cream
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Drapolene contains:
Benzalkonium chloride solution 0.02% w/w Equivalent to benzalkonium chloride 0.01% w/w Cetrimide 0.2% w/w
3 PHARMACEUTICAL FORM
Cream for topical application.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Drapolene is indicated for the relief of nappy rash and for use as an adjunct to baby care hygiene for the prevention of nappy rash.
Drapolene is indicated for the relief of urinary dermatitis in adults, and as an adjunct to patient care hygiene for the prevention of urinary dermatitis.
Drapolene is indicated for the symptomatic relief of minor burns, limited sunburn and the effects of weather.
4.2 Posology and method of administration
Route of administration: Topical Dosage:
Babies: The nappy area should be washed then dried thoroughly at each change of nappy. Drapolene Cream should be applied, paying particular attention to folds in the skin.
Adults: The affected area (or the area of application) should be washed and dried thoroughly before applying Drapolene. Regular routine application is advised.
Drapolene should be applied as required for minor burns, limited sunburn and the effects of weather.
Use in the Elderly:
No special comment
4.3 Contraindications
It is inadvisable to apply Drapolene Cream to a baby or adult who has an established hypersensitivity to benzalkonium chloride, cetrimide or lanolin. Use should be discontinued if an allergic hypersensitivity reaction is suspected.
4.4 Special warnings and precautions for use
The packs carry the following additional warnings:
Store below 25°C
For external use only
Keep out of the reach of children
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Fertility, pregnancy and lactation
When used in accordance with the specified indications, systemic absorption of the specified components is not envisaged and so there are no special precautions/warnings appropriate to pregnancy and lactation.
4.7 Effects on ability to drive and use machines
None.
4.8 Undesirable effects
Allergic hypersensitivity reactions may occur in individuals who are sensitive to one or several components of Drapolene Cream.
Hypersensitivity to lanolin is recognised but is rare.
In a few individuals, benzalkonium chloride, used as a preservative in ophthalmic solutions, was associated with oedema and conjunctivitis. Dermatitis as a result of contact allergy to benzalkonium chloride in plaster of Paris has also been reported.
Hypersensitivity to cetrimide is also known to occur, presenting as a localised contact dermatitis. In severe cases the rash may be generalised.
4.9 Overdose
There are no reports of adverse events resulting from excessive application or accidental ingestion of Drapolene Cream.
In cases of accidental ingestion, symptomatic treatment is appropriate.
5.1 Pharmacodynamic properties
Benzalkonium chloride and cetrimide are both quaternary ammonium disinfectants with properties typical of cationic surfactants. This preparation is useful in the treatment of and prevention of nappy rash, acting to suppress the development of ammonia producing organisms usually associated with this condition.
5.2 Pharmacokinetic properties
No data is available on the pharmacokinetics of the active ingredients of Drapolene Cream, when used for the specified indications. Systemic absorption of the active ingredients is not envisaged.
5.3 Preclinical safety data
None stated.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
White soft paraffin Wool fat (purified lanolin)
Cetyl alcohol Polawax Chlorocresol Amaranth Purified water
6.2 Incompatibilities
None known.
6.3 Shelf life
Tube - 36 months unopened.
Other packs - 36 months unopened.
6.4 Special precautions for storage
Store below 25°C.
6.5 Nature and contents of container
25, 75, 150, 200 or 350 g - white pigmented polypropylene containers with white pigmented LDPE snap-fit caps or white pigmented polypropylene containers with white pigmented LDPE/HDPE snap-fit caps.
500 g polypropylene pots with PVDC faced wad and polypropylene screw caps.
100 g polyolefin/foil/polyolefin laminate tubes with polypropylene caps.
6.6 Special precautions for disposal
None applicable.
7 MARKETING AUTHORISATION HOLDER
Omega Pharma Ltd.
1st Floor
32 Vauxhall Bridge Road LONDON SW1V 2SA United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 02855/0016
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
29/08/1989
DATE OF REVISION OF THE TEXT
21/12/2012
10